A potential blood test can distinguish ME/chronic fatigue syndrome with great accuracy, after years of medical uncertainty.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...

Single-cell research of patients’ immune cells to guide future treatments: Dr Arivusudar John: Shardul Nautiyal, Mumbai Friday, January 16, 2026, 08:00 Hrs [IST] Single-Cell Ana ...

HOUSTON, TEXAS / ACCESS Newswire / January 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for ar ...

Community Memorial Hospital (CMH) will replace its legacy health record systems with Oracle Health solutions to support ...

AI Nose commercial deployment accelerates in 2026 with dual-engine architecture, industrial expansion, and recurring SaaS revenue modelNew Trusval agreement commits to minimum 600-unit deployment, pos ...

Autoimmune diseases often present with overlapping, non-specific symptoms that complicate timely diagnosis and treatment. This complexity is magnified for individuals with polyautoimmunity, ...

Nearly 1.5 million Americans and nearly 5% of women over the age of 55 have rheumatoid arthritis (RA), an incurable ...

Private rheumatologist Dr Anandita Santosa in Singapore notes how current AI in healthcare priorities practically leave ...

Augurex CEO Neil Klompas describes why it is difficult for biomarkers to diagnose rheumatoid arthritis in some cases.

Threads is testing a new way for users to manipulate their own recommendation algorithm. The feature, aptly called "Dear algo," allows users to post a message to the algorithm with the note "dear algo ...